A 48-year-old Thai female, who had stage 2 carcinoma of the breast presented with recalcitrant erythrodermic psoriasis which was unresponsive to conventional therapies. She was prescribed 6 mg/kg day cyclosporin A. The erythroderma responded rapidly and was completely cleared within 3 weeks. The dosage was reduced in a step-wise manner to 4 and then 2 mg/kg day and was stopped after 2 months of treatment. Complete clearing of the skin lesion was observed without any side-effects except mild nausea. The patient was then referred to surgery for mastectomy and chemotherapy. There was no clinical relapse during more than 1 year of follow-up and at present she is continuing to do well.
BorelJF: The history of cyclosporin A and its significance. In: Cyclosporin A (WhiteDJG, ed). Amsterdam: Elsevier Biomedical Press, 1988; pp 5–17.
2.
KeownPAStillerCRCarruthersG: Cyclosporin: mechanism of action, measurement and clinical use. Br J Clin Pract1986; 40: 149–156.
3.
HessADColombaniPMEsaAH: Cyclosporin and the immune response: basic aspects. Immunology1986; 6: 123–149.
4.
SteinmullerDR: Cyclosporin and organ transplantation. Cleve Clin Q1985; 52: 263–270.
5.
Schmitz-SchumannM: Interim report of clinical studies presented at the International Symposium on Cyclosporin in Auto-immune Diseases, Basel, 18–20 March 1985. Prog Allergy 1986; 38: 436–446.
6.
PageEHWexlerDMGuentherLC: Cyclosporin A. J Am Acad Dermatol1986; 14: 785–791.
7.
BirenCABarrRJ: Dermatologic applications of cyclosporin. Arch Dermatol1986; 122: 1028–1032.
8.
ThivoletJBarthelemyHRigot-MullerG: Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet1985; i: 334–335.
